| |
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries
|
| |
| |
Download the PDF here
21 November 2022
Abstract
Long-acting injectable antiretroviral therapy (LAI-ART) for the treatment and prevention of human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by offering an alternative to daily oral medication. However, significant challenges at the drug, patient, and system levels risk impeding the uptake and implementation of LAI-ART. This review aims to describe the known and anticipated barriers to uptake of LAI-ART in high-income countries, as well as the ongoing research addressing some of these barriers to improve the delivery and uptake of LAI-ART products.
SYSTEM-LEVEL BARRIERS
Despite offering certain advantages over daily oral ART and PrEP, LAI formulations to treat and prevent HIV can be difficult to put into practice, beginning with getting these novel but costly formulations approved by healthcare payers. Even if reimbursed, their successful introduction requires not only an openness on the part of clinicians to alter their treatment approach but also a willingness by healthcare providers, administrators, and staff to adopt the necessary changes within their institution or medical practice to make the transition possible. The literature suggests that there may be a reluctance among members of the healthcare establishment to adopt and meaningfully implement injectable therapy, which would almost invariably require a shift in practice operations. Prior to CAB/RPV-LA receiving regulatory approval, a pre-implementation study among clinical and non-clinical stakeholders in Los Angeles County, California, found a significant level of concern about the potential of LAI-ART to disrupt workflows and place undue demand on workers [37].
|
|
| |
| |
|
|
|
